Christina Lindved appointed new Group CEO

The SSI Diagnostica Group (SSID Group) is delighted to announce the appointment of Christina Lindved as its new Group CEO effective from today. Christina has served on the board of Directors at SSID Group since 2018 and has extensive global Clinical Diagnostic leadership experience. Prior to joining SSID Group Christina has held senior executive positions across Dako, Agilent, Thermo Fisher Scientific and most recently Waters.

The SSID Group has also appointed a new Group CFO, Egil Madsen who brings 15 years of strong CFO experience from listed and PE backed companies latest in Atos Medical Group but also from MT Højgaard, Dako and FLSmidth Group.

Søren Skjold Mogensen, the prior CEO, will continue to be a key member of the executive management team. Søren has successfully helped grow SSID Group from a Danish microbiology company to a global entity with more than 600 employees including the acquisitions of CTK & BGB in 2020 and most recently Techlab in 2022. 

Chairman of the Board, Stig Løkke Pedersen says: “As SSID Group continues to evolve and expand within Infectious Disease Diagnostics the new and strengthened management team will help maximize the combined assets we have”.

Rasmus Molander, Co-Managing partner at Adelis Equity Partners also adds “SSID Group has shown significant organic growth in addition to acquisitions and is on an exciting growth journey within Rapid Tests and QC to vaccine manufacturing to mention a few. The new leadership team brings significant experience within the industry to help accelerate this success”.  

Together the new leadership team will focus on accelerating a global strategy leveraging the unique positioning of having access to global manufacturing and commercial footprint from which it can serve its customers and ultimately patients world-wide.

Stig Løkke Pedersen (Chairman of the Board)

Rasmus Molander (Co-Managing Partner at Adelis Equity Partners)